Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue
- PMID: 17605009
- DOI: 10.1007/s00262-007-0352-x
Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue
Abstract
Background: We previously demonstrated that targeting lymphotoxin alpha (LTalpha) to the tumor evokes its immunological destruction in a syngeneic B16 melanoma model. Since treatment was associated with the induction of peritumoral tertiary lymphoid tissue, we speculated that the induced immune response was initiated at the tumor site.
Methods and results: In order to directly test this notion, we analyzed the efficacy of tumor targeted LTalpha in LTalpha knock-out (LTalpha(-/-)) mice which lack peripheral lymph nodes. To this end, we demonstrate that tumor-targeted LTalpha mediates the induction of specific T-cell responses even in the absence of secondary lymphoid organs. In addition, this effect is accompanied by the initiation of tertiary lymphoid tissue at the tumor site in which B and T lymphocytes are compartmentalized in defined areas and which harbor expanded numbers of tumor specific T cells as demonstrated by in situ TRP-2/K(b) tetramer staining. Mechanistically, targeted LTalpha therapy seems to induce changes at the tumor site which allows a coordinated interaction of immune competent cells triggering the induction of tertiary lymphoid tissue.
Conclusion: Thus, our data demonstrate that targeted LTalpha promotes an accelerated immune response by enabling the priming of T cells at the tumor site.
Similar articles
-
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.Immunity. 2001 Feb;14(2):111-21. doi: 10.1016/s1074-7613(01)00094-2. Immunity. 2001. PMID: 11239444
-
Membrane lymphotoxin contributes to anti-leishmanial immunity by controlling structural integrity of lymphoid organs.Eur J Immunol. 2002 Jul;32(7):1993-2003. doi: 10.1002/1521-4141(200207)32:7<1993::AID-IMMU1993>3.0.CO;2-F. Eur J Immunol. 2002. PMID: 12115620
-
Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.Cancer Immunol Immunother. 2006 Jul;55(7):861-6. doi: 10.1007/s00262-005-0076-8. Epub 2005 Sep 13. Cancer Immunol Immunother. 2006. PMID: 16158274
-
Lymphocyte traffic in lymphoid organ neogenesis: differential roles of Ltalpha and LTalphabeta.Adv Exp Med Biol. 2002;512:43-8. Adv Exp Med Biol. 2002. PMID: 12405186 Review.
-
The role of lymphotoxin in development and maintenance of secondary lymphoid tissues.Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):275-88. doi: 10.1016/s1359-6101(03)00026-1. Cytokine Growth Factor Rev. 2003. PMID: 12787565 Review.
Cited by
-
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma.Front Immunol. 2024 Feb 1;15:1324093. doi: 10.3389/fimmu.2024.1324093. eCollection 2024. Front Immunol. 2024. PMID: 38361928 Free PMC article. Review.
-
Heterogeneity of tertiary lymphoid structures in cancer.Front Immunol. 2023 Dec 4;14:1286850. doi: 10.3389/fimmu.2023.1286850. eCollection 2023. Front Immunol. 2023. PMID: 38111571 Free PMC article. Review.
-
Turning up the heat: CTLA4 blockade in urothelial cancer.Nat Rev Urol. 2024 Jan;21(1):22-34. doi: 10.1038/s41585-023-00801-7. Epub 2023 Aug 22. Nat Rev Urol. 2024. PMID: 37608154 Review.
-
The link between T cell activation and development of functionally useful tumour-associated high endothelial venules.Discov Immunol. 2023 Apr 24;2(1):kyad006. doi: 10.1093/discim/kyad006. eCollection 2023. Discov Immunol. 2023. PMID: 37287625 Free PMC article. Review.
-
Modulation of T cell function and survival by the tumor microenvironment.Front Cell Dev Biol. 2023 May 18;11:1191774. doi: 10.3389/fcell.2023.1191774. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37274739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
